Twist Bioscience (TWST) CAO granted 5,633 PSUs; 60% vests 10/1/2026

Twist Bioscience (TWST) reported an equity award to its Chief Accounting Officer, Robert F. Werner.

Rhea-AI Filing Summary

Twist Bioscience (TWST) reported an equity award to its Chief Accounting Officer, Robert F. Werner. A Form 4 shows an acquisition of 5,633 shares at $0 on October 28, 2025, tied to performance stock units where target criteria were met.

According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement. Following the transaction, beneficial ownership stands at 52,046 shares, held directly.

Insights

Equity Compensation Analyst

Routine PSU vesting milestone recognized; majority vests on schedule.

The officer reported acquisition of 5,633 shares at $0, stemming from performance stock units whose target criteria were met on October 28, 2025. This reflects the accounting recognition of earned PSUs rather than an open-market purchase.

Per the terms, 60% of the PSUs remain time-based and are scheduled to vest on October 1, 2026, contingent on continued service or possible acceleration under the award agreement. Cash outlay is not indicated, consistent with stock-based awards.

This is an administrative disclosure typical for executive compensation. Actual share issuance over time will depend on the vesting schedule specified in the award agreement.

Insider Trade Summary

Grant/Award: 5,633 shares

Grant/Award 1 txn

Insider WERNER ROBERT F.

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,633	$0.00	$0.00

Holdings After Transaction: Common Stock — 52,046 shares (Direct)

Footnotes (1)

1. F1. Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Twist Bioscience (TWST) disclose in this Form 4?

An acquisition of 5,633 shares at $0 tied to performance stock units where target criteria were met on October 28, 2025.

Who is the reporting person in TWST’s Form 4 and what is their role?

The reporting person is Robert F. Werner, Chief Accounting Officer of Twist Bioscience.

What is the vesting schedule for the reported PSUs at TWST?

60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration as provided.

How many TWST shares does the officer beneficially own after the transaction?

Beneficial ownership is 52,046 shares, held directly.

Was there a purchase price for the TWST shares reported?

The transaction price is reported as $0, consistent with stock-based award settlement rather than an open-market purchase.

What triggered the PSU award recognition at TWST?

The target criteria for the performance stock units were determined to have been met on October 28, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2025		A		5,633(1)	A	$0	52,046	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.